Serum adiponectin and markers of endothelial dysfunction in stable angina pectoris patients undergoing coronary artery bypass grafting (CABG)

Advances in Medical Sciences

Volumn 59, Issue 2, 2014, Pages 245-249

  Lisowska, Anna ^a   Lisowski, Piotr ^a   Knapp, Malgorzata ^a   Tycinska, Agnieszka ^a   Sawicki, Robert ^a   Malyszko, Jolanta ^a   Hirnle, Tomasz ^a   Musial, Wlodzimierz Jerzy ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Adiponectin; CD146; Coronary artery bypass grafting (CABG); Coronary artery disease (CAD); Thrombomodulin (TM); Von Willebrand factor (VWF)

Indexed keywords

ADIPONECTIN; CD146 ANTIGEN; CELL ADHESION MOLECULE; THROMBOMODULIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; HUMAN; MALE; MIDDLE AGED; SMOKING; STABLE ANGINA PECTORIS;

EID: 84908404198     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.1016/j.advms.2014.05.001     Document Type: Article

References (19)

1. Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003;361(January (9353)):226-8.
2. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23(January (1)):85-9.
3. Bardin N, Anfosso F, Masse JM, Cramer E, Sabatier F, Le Bivic A, et al. Identification of CD146 as a component of the endothelial junction in the control of cell-cell cohesion. Blood 2001;98(December (13)):3677-84.
4. Bardin N, George F, Mutin M, Brisson C, Horschowski N, Francés V, et al. S-Endo 1, a pan endothelial monoclonal antibody recognizing a novel human endothelial antigen. Tissue Antigens 1996;48(November (5)):531-9.
5. Bardin N, Moal V, Anfosso F, Daniel L, Brunet P, Sampol J, et al. Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. Thromb Haemost 2003;90(November (5)):915-20.
6. Wang F, Xing T, Wang N, Liu L. Clinical significance of plasma CD146 and P-selectin in patients with type 2 diabetic nephropathy. Cytokine 2012;57(January (1)):127-9.
7. Valen G, Blomback M, Sellei P, Lindblom D, Vaage J. Release of von Willebrand factor by cardiopulmonary bypass, but not by cardioplegia in open heart surgery. Thromb Res 1994;73(January (1)):21-9.
8. Kre¸cki R, Krzemińska-Pakuła M, Peruga J, Szczes̈niak P, Lipiec P, Orszulak-Michalak D, et al. Influence of treatment strategy on serum adiponectin, resistin and angiogenin concentrations in patients with stable multivessel coronary artery disease after one-year follow-up. Kardiol Pol 2010;68(December (12)):1313-20.
9. Sung SH, Wu TC, Huang CH, Lin SJ, Chen JW. Prognostic impact of body mass index in patients undergoing coronary artery bypass surgery. Heart 2011;97(April (8)):648-54.
10. Lisowska A, Tycińska A, Knapp M, Sawicki R, Lisowski P, Musiał WJ, et al. Adiponectin - an independent marker of coronary artery disease occurrence rather than a degree of its advancement in comparison to the IMT values in peripheral arteries. Clin Chim Acta 2012;413(April (7-8)):749-52.
11. Schnabel R, Messow CM, Lubos E, Espinola-Klein C, Rupprecht HJ, Bickel C, et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur Heart J 2008;29(March (5)):649-57.
12. Dunajska K, Milewicz A, Jedrzejuk D, Szymczak J, Kuliczkowski W, Salomon P, et al. Plasma adiponectin concentration in relation to severity of coronary atherosclerosis and cardiovascular risk factors in middle-aged men. Endocrine 2004;25(December (3)):215-21.
13. Iwashima Y, Horio T, Kumada M, Suzuki Y, Kihara S, Rakugi H, et al. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol 2006;98(December (12)):1603-8.
14. Lindsay RS, Resnick HE, Zhu J, Tun ML, Howard BV, Zhang Y, et al. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2005;25(March (3)):e15-6.
15. Małyszko J, Małyszko JS, Brzosko S, Wołczynski S, Mys̈liwiec M. Markers of endothelial cell activation/injury: CD146 and thrombomodulin are related to adiponectin in kidney allograft recipients. Am J Nephrol 2005;25(May-June (3)):203-10.
16. Saito T, Saito O, Kawano T, Tamemoto H, Kusano E, Kawakami M, et al. Elevation of serum adiponectin and CD146 levels in diabetic nephropathy. Diabetes Res Clin Pract 2007;78(October (1)):85-92.
17. Conri C, Seigneur M, Constans J, Mercier P, Baste JC, Dufourcq P, et al. Evidence of elevated soluble plasma thrombomodulin in atherosclerosis. J Mal Vasc 1993;18(2):112-8.
18. Bohrer H, Bottiger BW, Haussmann R, Nawroth PP, Motsch J, Martin E. Thrombomodulin as endothelial cell marker in heart surgery patients. Anasthesiol Intensivmed Notfallmed Schmerzther 1995;30(November (7)):417-9.
19. Tsang GM, Allen S, Pagano D, Wong C, Graham TR, Von Bonser RS. Willebrand factor and urinary albumin excretion are possible indicators of endothelial dysfunction in cardiopulmonary bypass. Eur J Cardiothorac Surg 1998;13(April (4)):385-91.